World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
41753
World Ranking
10319
National Ranking
5307

Research.com Recognitions

  • 2013 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Karl Kieburtz is affiliated with the University of Rochester Medical Center in the United States. Their research predominantly spans the fields of Medicine and Neuroscience, with a specialization in subfields such as Neurology, Cellular and Molecular Neuroscience, Cognitive Neuroscience, Psychiatry and Mental Health, and Molecular Biology.

Their work primarily focuses on topics including Parkinson's Disease Mechanisms and Treatments, Neurological Disorders and Treatments, Botulinum Toxin and Related Neurological Disorders, Genetic Neurodegenerative Diseases, Autism Spectrum Disorder Research, Dementia and Cognitive Impairment Research, and Nuclear Receptors and Signaling.

Frequent publication venues for their research include Movement Disorders, Neurology, Journal of Parkinson's Disease, bioRxiv (Cold Spring Harbor Laboratory), and Journal of Huntington's Disease.

Kieburtz has collaborated regularly with several researchers, notably Lana M. Chahine, Caroline M. Tanner, Andrew Siderowf, Tanya Simuni, and Kenneth Marek.

Some recent papers authored or coauthored by Kieburtz include:

  • Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression, 2020, Movement Disorders
  • Remote smartphone monitoring of Parkinson's disease and individual response to therapy, 2021, Nature Biotechnology
  • GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop, 2020, Journal of Parkinson s Disease
  • Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial, 2023, The Lancet Neurology
  • Trichloroethylene: An Invisible Cause of Parkinson's Disease?, 2023, Journal of Parkinson s Disease

Kieburtz was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2013.

Best Publications

  • Unified huntington’s disease rating scale: Reliability and consistency

    Karl Kieburtz;John B. Penney;Peter Corno;Neal Ranen

  • Levodopa and the progression of Parkinson's disease.

    Fahn S;Oakes D;Shoulson I;Kieburtz K

  • Projected number of people with parkinson disease in the most populous nations, 2005 through 2030

    E. R. Dorsey;R. Constantinescu;R. Constantinescu;J. P. Thompson;K. M. Biglan

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

    RS Rachelle S. Doody;RG Ronald G. Rg Thomas;Martin Farlow;Takeshi Iwatsubo

  • Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

    Clifford W. Shults;David Oakes;Karl Kieburtz;M. Flint Beal

  • A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

    Rachelle S. Doody;Rema Raman;Martin Farlow;Takeshi Iwatsubo

  • Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy: A Randomized Trial

    Jerome Engel;Michael P. McDermott;Samuel Wiebe;John T. Langfitt

  • Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

    C Warren Olanow;Karl Kieburtz;Per Odin;Alberto J Espay

  • Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

    William J Marks;Raymond T Bartus;Joao Siffert;Charles S Davis

  • A controlled trial of rasagiline in early Parkinson disease: The tempo study

    Andrew Siderowf;Matthew Stern;Ira Shoulson;Karl Kieburtz

  • HIV-associated cognitive impairment before and after the advent of combination therapy

    Ned Sacktor;Ned Sacktor;Michael P. McDermott;Karen Marder;Giovanni Schifitto

  • Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

    Robert G Holloway;Ira Shoulson;Stanley Fahn;Karl Kieburtz

  • The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

    Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  • Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease: Risk Factors forL-Dopa Induced Motor Complications

    C. Warren Olanow;Karl Kieburtz;Olivier Rascol;Werner Poewe

  • Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

    John B. Penney;David Oakes;Ira Shoulson;Stanley Fahn

  • Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

    Michael Wall;Michael P. McDermott;Karl D. Kieburtz;James J. Corbett

  • Rate of functional decline in Huntington’s disease

    K. Marder;H. Zhao;R. H. Myers;M. Cudkowicz

  • The idiopathic intracranial hypertension treatment trial clinical profile at baseline

    Michael Wall;Mark J. Kupersmith;Karl D. Kieburtz;James J. Corbett

  • Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy: A Randomized Trial

    Jerome Engel;Michael P. Mcdermott;Samuel Wiebe;John T. Langfitt

Frequent Co-Authors

Michael P. McDermott
Michael P. McDermott University of Rochester
Ira Shoulson
Ira Shoulson Georgetown University
Caroline M. Tanner
Caroline M. Tanner University of California, San Francisco
Scott Y. H. Kim
Scott Y. H. Kim National Institutes of Health
C. Warren Olanow
C. Warren Olanow Icahn School of Medicine at Mount Sinai
Kenneth Marek
Kenneth Marek Institute for Neurodegenerative Disorders
Andrew Siderowf
Andrew Siderowf University of Pennsylvania
Karen Marder
Karen Marder Columbia University
Brit Mollenhauer
Brit Mollenhauer University of Göttingen
Robert A. Hauser
Robert A. Hauser University of South Florida

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, there are several related online degrees and career pathways worth exploring. The healthcare field offers a wide range of in-demand roles, many of which can be accessed through flexible, online programs.

For those interested in administrative roles, consider pursuing the cheapest medical coding certification online. This path provides a cost-effective entry into healthcare by focusing on vital billing and coding skills.

If your passion is clinical care, nursing remains a highly respected and rewarding option. Explore the cheapest online nursing program to launch your nursing journey while keeping tuition costs manageable.

For advanced practice or greater autonomy, becoming a nurse practitioner is a logical step. Programs like the cheapest online nurse practitioner programs help you do so affordably.

Lastly, if research or academic leadership interests you, consider a doctoral path by reviewing phd nursing programs online. These programs are designed for working nurses seeking the highest levels of expertise without disrupting their careers.

Best Scientists Citing Karl Kieburtz

Trending Scientists

Recently Published Articles